07:17 AM EDT, 04/24/2026 (MT Newswires) -- Moberg Pharma (MOB.ST) said Friday it added new markets in its exclusive licensing deal with Karo Healthcare for nail fungus treatment MOB-015.

As agreed, Sweden-based Karo Healthcare may also commercialize MOB-015 in Australia, New Zealand, South Korea, and Taiwan, under the brand name Lamisil. The companies'initial collaboration covered 19 European markets.

Financial terms of the deal were not disclosed.

Ämnen i artikeln

Moberg Pharma

Senast

12,38

1 dag %

−0,16%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån